Core Viewpoint - Xinhua Medical (600587.SH) is strategically focusing on innovation and collaboration with its investee company, Huajian Medical (01931), which it holds a 27.29% stake in, indicating a significant shift towards a new business model in the medical sector [1][4]. Group 1: Investment Structure and Strategic Collaboration - Xinhua Medical holds 443.7 million shares of Huajian Medical through its wholly-owned subsidiary, Hualun International, and uses the equity method to account for investment income [4]. - The company has appointed two directors to participate in Huajian Medical's board of 11 members, emphasizing its commitment to strategic oversight [4]. - Xinhua Medical has expressed a strong focus on industry risks and opportunities, providing credibility to Huajian Medical's innovative path [4]. Group 2: Strategic Developments of Huajian Medical - Since July, Huajian Medical has undergone a strategic upgrade centered on "reconstructing the medical innovation asset chain," initiating a dual primary listing in the U.S. [4]. - Key initiatives launched include the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins, along with a partnership to establish a tokenized fund for innovative drug intellectual property [4][5]. - In August, Huajian Medical accelerated its strategy by launching a global enhanced Ethereum (ETH) treasury and forming a strategic partnership with HashKey, completing a compliant purchase of 149 million HKD in ETH [5]. Group 3: Market Impact and Future Prospects - The strategic moves aim to address pain points in pharmaceutical innovation by leveraging blockchain technology for intellectual property rights, pricing, and cross-border transactions [5]. - Xinhua Medical's cautious stance suggests potential strategic collaboration opportunities with Huajian Medical regarding its U.S. IPO, with the value of Xinhua Medical's stake in Huajian Medical reaching 4.1 billion HKD based on a market valuation of 15 billion HKD [5][6]. - The integration of stablecoins, Ethereum, and the RWA exchange is expected to create a multi-layered value system that could reshape traditional pharmaceutical intellectual property trading [6][7].

智通财经APP获悉，近日，A股上市公司新华医疗(600587.SH)在投资者互动平台的密集发声，悄然揭开了参股企业华检医疗 (01931)的战略转型图景。面对投资者关于公司之于华检医疗的股权结构、业务协同及加密资产布局等核心关切问题，这家持有 华检医疗27.29%股份的医疗器械龙头，始终传递出对创新路径的战略重视。 随着美国稳定币牌照申请、以太坊(ETH)金库扩容及基金运作的实质推进，这条医疗创新药的"链上高速公路"正驶入落地关键 期。而新华医疗持续关注的背后，是对医疗科技与金融科技融合趋势的敏锐把握——在股东的战略赋能下，华检医疗这场颠覆 性实验，或将成为中国创新药出海的新基建。 (来源：东方财富新华医疗股吧"问董秘"板块) 公开信息显示，新华医疗明确表示通过全资子公司华伦国际持有华检医疗4.437亿股，采用权益法核算投资收益，并委派2名董 事参与华检医疗11人董事会的决策。在回应中，新华医疗多次强调"持续关注行业风险与机遇"，并对医疗创新药RWA交易所生 态给予"提供新发展思路"的积极评价，为华检医疗的破局之路注入关键的股东公信力。 市场的高度聚焦，源于华检医疗今年7月以来疾风骤雨般的战略升级。这场以"医 ...